From October 1, 2021 to October 31, 2021, the company has repurchased 273,210 shares, representing 0.19% for $9.5 million. With this, the company has completed the repurchase of 22,250,346 shares, representing 15.7% for $550 million under the buyback announced on November 4, 2019.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.15 USD | -1.57% | +8.12% | +16.75% |
May. 07 | Halozyme Therapeutics Q1 Non-GAAP Earnings, Revenue Rise; 2024 Guidance Reaffirmed | MT |
May. 07 | Transcript : Halozyme Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.75% | 5.58B | |
+3.91% | 108B | |
+10.87% | 104B | |
+1.28% | 22.33B | |
-13.14% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-10.66% | 17.64B | |
+3.75% | 14.05B | |
+36.70% | 12.51B |
- Stock Market
- Equities
- HALO Stock
- News Halozyme Therapeutics, Inc.
- Tranche Update on Halozyme Therapeutics, Inc.'s Equity Buyback Plan announced on November 4, 2019.